
US Approves First Drug For Rare Neurological Disorder
What Happened?
The US FDA has approved Infilbray, the first drug targeting neurological symptoms of Type 3 Gaucher disease, offering new hope for affected patients.
Key points
- Infilbray is the first drug approved for Type 3 Gaucher disease.
- It targets neurological symptoms, unlike previous treatments focused on organ effects.
- The drug is taken orally once daily and can cross the blood-brain barrier.
- Clinical trials showed significant improvement in muscle coordination and cognitive function.
- Side effects may include gastrointestinal issues and psychiatric risks.
- The approval applies to adults and children weighing at least 15 kg.
Key insights
- Infilbray's ability to cross the blood-brain barrier may change treatment approaches for neurological disorders.
- The drug could lead to improved quality of life for patients with Type 3 Gaucher disease.
- Potential side effects highlight the need for careful patient monitoring during treatment.
Why it matters
This approval could provide new treatment options for patients with limited choices for managing neurological symptoms.
Tags
Entities
Source
Times Now